I think many of us forget about Kevetrin but there
Post# of 72444
(Total Views: 303)
Posted On: 08/03/2017 11:13:07 PM
I think many of us forget about Kevetrin but there it is quietly chugging away in the background.
I'm betting that one of the below companies has requested the MOA data to see how it dovetails with their struggling P53 attempts.
"On Sunday December 23rd, 2012, I saw a front page article in The New York Times by Gina Kolata titled "A Single Drug To Kill Cancers In Many Forms." Kolata said, "For the first time ever, three pharmaceutical companies are poised to test whether new drugs can work against a wide range of cancers independently of the organ where the cancer originated--breast, brain, prostate, liver, lung or kidney. The drugs go after an aberration involving a cancer gene, p53, fundamental to tumor growth. Many scientists are seeing this as the beginning of a new genetic age in cancer research."
Who are the three companies mentioned as "racing" to develop separate versions of these blockbuster therapeutics for many forms of cancer? Merck (NYSE: MRK), Roche (OTCQX:RHHBY) and Sanofi (NYSE: SNY). According to Kolata, it seems those three are the companies most deserving of national recognition. However, if Kolata would have looked a little deeper, she might have found reason to mention Pfizer (NYSE: PFE)."
"And where has this research on p53 been conducted? For Roche in Europe; for Merck in the United States; and for Sanofi in the US at the University of Michigan."
"The key word for this 6-year research era was "Nutlins," the discovery of a small molecule that could enter the small opening between the MDM2 and the p53 and pry them apart. Kolata properly summarizes that Nutlins were simply unable to be absorbed by the human body and therefore Roche's big investment was not able to be considered as a potential for human trials. Simply put, Roche developed a cancer cure for mice, but not for humans."
https://www.google.com/amp/s/seekingalpha.com...g-p53-race
"Can combination therapy extend the benefits of immunotherapy?
Immunotherapies that turn the body into a weapon against cancer have produced some remarkable results, extending the lives of patients by months or years longer than doctors would have expected. But they still only work in a minority of between 20 and 30 per cent of patients.
The Big Read
T cells attacking cancer cell, coloured scanning electron micrograph (SEM). The T cells (red) are attacking an oral squamous cancer cell (white). The cytotoxic (cell-killing) T cells are part of a natural immune response. Research being carried out in the field of nanomedicine is creating personalized cancer vaccines by loading neoantigens from a patient's tumour into nanoparticles. These nanoparticles are then used to activate the patient's own immune system, triggering the actions of T cells as seen here.
Big pharma faces costly setback in cancer fight
Investors lose billions as immunotherapies fall short of high expectations
Drugmakers have argued that they can boost the number of people who respond by combining immunotherapies with other drugs, and have initiated a flurry of clinical trials. Among the studies that have generated the most interest is a trial of Keytruda in combination with an experimental drug being developed by Incyte, a biotech group."
https://www.google.com/amp/s/amp.ft.com/conte...6b95f30f58
I'm betting that one of the below companies has requested the MOA data to see how it dovetails with their struggling P53 attempts.
"On Sunday December 23rd, 2012, I saw a front page article in The New York Times by Gina Kolata titled "A Single Drug To Kill Cancers In Many Forms." Kolata said, "For the first time ever, three pharmaceutical companies are poised to test whether new drugs can work against a wide range of cancers independently of the organ where the cancer originated--breast, brain, prostate, liver, lung or kidney. The drugs go after an aberration involving a cancer gene, p53, fundamental to tumor growth. Many scientists are seeing this as the beginning of a new genetic age in cancer research."
Who are the three companies mentioned as "racing" to develop separate versions of these blockbuster therapeutics for many forms of cancer? Merck (NYSE: MRK), Roche (OTCQX:RHHBY) and Sanofi (NYSE: SNY). According to Kolata, it seems those three are the companies most deserving of national recognition. However, if Kolata would have looked a little deeper, she might have found reason to mention Pfizer (NYSE: PFE)."
"And where has this research on p53 been conducted? For Roche in Europe; for Merck in the United States; and for Sanofi in the US at the University of Michigan."
"The key word for this 6-year research era was "Nutlins," the discovery of a small molecule that could enter the small opening between the MDM2 and the p53 and pry them apart. Kolata properly summarizes that Nutlins were simply unable to be absorbed by the human body and therefore Roche's big investment was not able to be considered as a potential for human trials. Simply put, Roche developed a cancer cure for mice, but not for humans."
https://www.google.com/amp/s/seekingalpha.com...g-p53-race
"Can combination therapy extend the benefits of immunotherapy?
Immunotherapies that turn the body into a weapon against cancer have produced some remarkable results, extending the lives of patients by months or years longer than doctors would have expected. But they still only work in a minority of between 20 and 30 per cent of patients.
The Big Read
T cells attacking cancer cell, coloured scanning electron micrograph (SEM). The T cells (red) are attacking an oral squamous cancer cell (white). The cytotoxic (cell-killing) T cells are part of a natural immune response. Research being carried out in the field of nanomedicine is creating personalized cancer vaccines by loading neoantigens from a patient's tumour into nanoparticles. These nanoparticles are then used to activate the patient's own immune system, triggering the actions of T cells as seen here.
Big pharma faces costly setback in cancer fight
Investors lose billions as immunotherapies fall short of high expectations
Drugmakers have argued that they can boost the number of people who respond by combining immunotherapies with other drugs, and have initiated a flurry of clinical trials. Among the studies that have generated the most interest is a trial of Keytruda in combination with an experimental drug being developed by Incyte, a biotech group."
https://www.google.com/amp/s/amp.ft.com/conte...6b95f30f58
(1)
(0)